CARGO Therapeutics Statistics
Total Valuation
CRGX has a market cap or net worth of $173.52 million. The enterprise value is -$202.74 million.
Important Dates
The next estimated earnings date is Thursday, March 20, 2025, after market close.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRGX has 46.03 million shares outstanding. The number of shares has increased by 5,912.46% in one year.
| Current Share Class | 46.03M |
| Shares Outstanding | 46.03M |
| Shares Change (YoY) | +5,912.46% |
| Shares Change (QoQ) | +9.97% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 77.43% |
| Float | 27.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.43 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.95, with a Debt / Equity ratio of 0.07.
| Current Ratio | 18.95 |
| Quick Ratio | 18.84 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.81% and return on invested capital (ROIC) is -45.50%.
| Return on Equity (ROE) | -69.81% |
| Return on Assets (ROA) | -40.35% |
| Return on Invested Capital (ROIC) | -45.50% |
| Return on Capital Employed (ROCE) | -40.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 116 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.93% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -83.93% |
| 50-Day Moving Average | 10.66 |
| 200-Day Moving Average | 16.49 |
| Relative Strength Index (RSI) | 24.94 |
| Average Volume (20 Days) | 2,192,303 |
Short Selling Information
The latest short interest is 4.31 million, so 9.37% of the outstanding shares have been sold short.
| Short Interest | 4.31M |
| Short Previous Month | 7.21M |
| Short % of Shares Out | 9.37% |
| Short % of Float | 15.76% |
| Short Ratio (days to cover) | 2.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -172.19M |
| Pretax Income | n/a |
| Net Income | -154.14M |
| EBITDA | -169.79M |
| EBIT | -172.19M |
| Earnings Per Share (EPS) | -$4.01 |
Full Income StatementBalance Sheet
The company has $404.85 million in cash and $28.58 million in debt, giving a net cash position of $376.26 million or $8.17 per share.
| Cash & Cash Equivalents | 404.85M |
| Total Debt | 28.58M |
| Net Cash | 376.26M |
| Net Cash Per Share | $8.17 |
| Equity (Book Value) | 400.88M |
| Book Value Per Share | 8.72 |
| Working Capital | 388.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$133.84 million and capital expenditures -$6.43 million, giving a free cash flow of -$140.27 million.
| Operating Cash Flow | -133.84M |
| Capital Expenditures | -6.43M |
| Free Cash Flow | -140.27M |
| FCF Per Share | -$3.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |